|
|
||||||||
Ann Thorac Surg 2006;82:1802-1807
© 2006 The Society of Thoracic Surgeons
a Department of Thoracic Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan
b Department of Diagnostic Pathology, Graduate School of Medicine, Chiba University, Chiba, Japan
c Department of Respirology, Graduate School of Medicine, Chiba University, Chiba, Japan
d Division of Thoracic Diseases, Chiba Cancer Center, Chiba, Japan
Accepted for publication May 22, 2006.
* Address correspondence to Dr Fujisawa, Department of Thoracic Surgery, Graduate School of Medicine, Chiba University, 1-8-1, Inohana, Chuo-ku, Chiba 260-8670 Japan. (Email: fujisawat{at}faculty.chiba-u.jp).
BACKGROUND: Patients with pulmonary large cell neuroendocrine carcinoma (LCNEC) have a very poor prognosis, but the benefit of adjuvant chemotherapy for these patients has not been established. We performed a prospective analysis of adjuvant chemotherapy for patients with completely resected pulmonary LCNECs to assess the effect of adjuvant chemotherapy.
METHODS: The adjuvant mixture consisted of cisplatin and VP-16 and was administered after surgery to 15 patients with LCNECs from 2000 to 2005. We compared patient survival with historical data for LCNEC patients treated without platinum-based adjuvant chemotherapy after surgery.
RESULTS: There were no differences in age, gender, surgical methods, and staging between the adjuvant chemotherapy group and the control group. Median follow-up was 33 months for the adjuvant group and 42 months for the control group. Of the 15 patients in the adjuvant chemotherapy group, 2 patients had disease recurrence and 1 died of interstitial pneumonia. The overall survival rate at 2 and 5 years of patients with adjuvant chemotherapy was 88.9%. The overall survival rate between patients with adjuvant chemotherapy and the historical control group was significantly different.
CONCLUSIONS: Adjuvant chemotherapy consisting of cisplatin and VP-16 after surgery appears promising for the improvement of the prognosis for patients with completely resected LCNECs, and it should be evaluated further in larger multi-institutional trials.
Related Article
Ann. Thorac. Surg. 2006 82: 1807.
This article has been cited by other articles:
![]() |
A. Iyoda, K. Hiroshima, Y. Moriya, Y. Iwadate, Y. Takiguchi, T. Uno, Y. Nakatani, and I. Yoshino Postoperative recurrence and the role of adjuvant chemotherapy in patients with pulmonary large-cell neuroendocrine carcinoma. J. Thorac. Cardiovasc. Surg., August 1, 2009; 138(2): 446 - 453. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Iyoda, K. Hiroshima, Y. Nakatani, and T. Fujisawa Pulmonary Large Cell Neuroendocrine Carcinoma: Its Place in the Spectrum of Pulmonary Carcinoma Ann. Thorac. Surg., August 1, 2007; 84(2): 702 - 707. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. Morandi and C. Casali Invited Commentary Ann. Thorac. Surg., November 1, 2006; 82(5): 1807 - 1807. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |